Focus topics


Report: Delayed approval of BioNTech

Apparently, China wants to give preference to a self-developed mRNA vaccine instead of approving the German product from BioNTech. The Wall Street Journal quotes informed circles as saying that the approval procedure for the BioNTech preparation is currently deliberately delayed. The reason is concern about confidence in homegrown vaccines. Accelerated approval of the state-of-the-art ingredient from the West could therefore create the impression that the products from Sinopharm and Sinovac are second-class vaccines.

Continue reading now

Get 30 days of free access to the Decision Brief to read these and more quality news every day.

Are you already a guest at the China.Table? Log in now

Related

    Xi arrives in Hong Kong
    International reputation suffers
    VW CEO: partners inform us about human rights
    Ifo: Reduce raw material dependence on China